Hypolipidemics Global Market Report 2021 Featuring Abbott Laboratories, Apotex Fermentation, Biocon, Cadila Healthcare and Chunghwa Chem Syn & Biotech
DUBLIN, December 02, 2021 - (BUSINESS WIRE) - The report "Hypolipidemis Global Market Report 2021: COVID-19 Impact and Recovery to 2030" has been added ResearchAndMarkets.com to offer. The global hypolipidemia market is forecast to decline from $ 16.23 billion in 2020 to $ 15.94 billion in 2021, with an average annual growth rate (CAGR) of -1.8%. The decline is mainly due to the fact that companies' production was negatively impacted by COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of commercial activities that created operational challenges. The market is expected to reach $ 18.41 billion in 2025 at a CAGR of 3.7%. Key players in the Hypolipidemic Drugs market are Abbott Laboratories Ltd, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, and Chunghwa Chem Syn & Biotech Co., Ltd. Hypolipidemic Drugs market consists of hypolipidemic drug sales and related services